176961-53-8

Basic information

• Product Name: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE
• Synonyms: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE;1H-IMidazole,2-(4-broMophenyl)-;2-(4-BroMophenyl)iMidazole
• CAS NO: 176961-53-8
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.07
• EINECS: 200-002-4
• Mol File: 176961-53-8.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 383.41 °C at 760 mmHg
• Flash Point: 185.68 °C
• Appearance: /
• Density: 1.566 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.636
• CAS DataBase Reference: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(176961-53-8)
• EPA Substance Registry System: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(176961-53-8)

Safety Data

• Hazardous Substances Data: 176961-53-8(Hazardous Substances Data)

Usage

General Description

2-(4-Bromo-phenyl)-1H-imidazole is a chemical compound with the molecular formula C9H7BrN2. It is a heterocyclic organic compound that contains an imidazole ring with a bromine-substituted phenyl group. 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE is commonly used in pharmaceutical and medicinal research as it has been found to exhibit various biological activities, including anti-fungal, anti-bacterial, and anti-inflammatory properties. Its structure and properties make it a valuable tool in drug discovery and development, and it is of interest to researchers working to develop new therapeutic agents. Additionally, the presence of the bromine substituent makes it useful for applications in organic synthesis and chemical reactions.

InChI:InChI=1/C9H7BrN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-6H,(H,11,12)

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 107-15-3 ethylenediamine 
• 131543-46-9 Glyoxal 
• 623-00-7 4-bromobenzenecarbonitrile 
• 22483-09-6 2,2-dimethoxyethylamine 
• 288-32-4 1H-imidazole 
• 106-40-1 4-bromo-aniline 
• 586-75-4 4-chlorobenzoyl chloride 
• 206535-83-3 2-(4-bromophenyl)-4,5-dihydro-1H-imidazole 

Downstream Products

• 934744-50-0 2-(4-bromophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 
• 1269646-23-2 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 
• 1269646-25-4 (S)-4-isopropyl-3-(3-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)oxazolidin-2-one 
• 1269643-37-9 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-isopropyloxazolidin-2-one 
• 1269643-42-6 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-phenyloxazolidin-2-one 
• 1332526-28-9 2-(4-bromophenyl)-1-(phenylsulfonyl)-1H-imidazole 
• 1618658-98-2 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide 
• 1229583-68-9 3-[4-(1H-imidazol-2-yl)-phenyl]-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine 
• 1021916-67-5 6-(4-(1H-imidazol-2-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 
• 1256956-07-6 isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate 
• 1229584-17-1 2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazole 
• 1021919-39-0 2-(4-(trimethylstannyl)phenyl)-1H-imidazole 

Relevant articles and documents

A sustainable approach towards the three-component synthesis of unsubstituted 1H-imidazoles in the water at ambient conditions

A green protocol for the synthesis of unsubstituted imidazoles has been demonstrated herein. The reaction is realized using commercially available lipase enzyme, porcine pancreas lipase (PPL) in water. The reaction conditions are selective and mild which helped to tolerate a wide variety of functional groups to give the desired products in good chemical yields. (Figure presented.).

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular disease, demyelinat